Navigation Links
BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
Date:1/10/2008

pect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection may not be correct, that DHHS and the FDA may not agree with our analysis, that DHHS may further condition, reduce or eliminate future funding of the peramivir program, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in CTCL may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient c
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. Medpace Strengthens Presence in Central Europe
5. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
6. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
7. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
8. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
9. Anavex strengthens Board of Directors
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015 According to a new ... by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), ... CRO) - Global Forecast to 2020", published by MarketsandMarkets, the ... 2020 from $107.56 Million in 2015, at a CAGR of ... and 67 F igures spread through 125 ...
(Date:6/29/2015)... NEW YORK , June 29, 2015   For ... of life sciences to assess their overall digital maturity ... to show that these companies are not maturing fast ... the healthcare industry in numerous ways overall and customers ... industries in terms of digital customer engagement.  ...
(Date:6/26/2015)... , June 26, 2015   ... ), a pet therapeutics company focused on ... biopharmaceutical products for companion animals, today announced ... study of capromorelin (AT-002), the company,s innovative ... is a small molecule that mimics ghrelin, ...
(Date:6/26/2015)...  A San Francisco company, Pembient, recently announced it ... horn: beer in China and ... response to the emerging industry, two leading rhino conservation ... synthetic rhino horn.  The International ... International (SRI) released a joint statement ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.506 12/2001 , , ... , , , Microorganism , ... Cell type , Bacteria, gram negative, ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.538 04/2002 , , , ... , Microorganism , ... Cell type , Bacteria, gram positive, , ...
... , Multiporator / Electroporator 2510 , , , , , , ... Protocol , Protocol No. 4308 915.502 12/2001 , , ... , , Microorganism , ... Cell type , Bacteria, gram negative, , ...
Cached Biology Technology:Borrelia burgdorferi 2Bifidobacterium animalis 2Agrobacterium tumefaciens 2
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... the Southern Ocean, large quantities of surface-drifting plankton algae are ... surface waters, which can affect the global carbon dioxide cycle. ... which has just drawn to a close in Cape Town ... Wegener Institute, part of the Helmholtz Association. On February 5, ...
... Rochet, a research scientist at IFREMER (The French Research ... the prestigious Pew Fellowship in Marine Conservation to determine ... to the delicately balanced marine ecosystem. She will use ... use of that technique, and to further improve its ...
... YORK CITY - Dr. Ussif Rashid Sumaila, an Associate ... in Vancouver, Canada, is among five ocean experts to ... Conservation, which supports critical marine conservation projects around the ... the financial factors contributing to unsustainable commercial fishing and ...
Cached Biology News:Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 2Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 3Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 42008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 22008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 32008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 42008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 22008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 32008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 4
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
...
Biology Products: